ConductScience.org, home

Paper42979192PubMed

Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis.

Leng J and 2 others. Front Immunol, 2026.

Cite this record

ConductScience Library. Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis. Papers, record 42979192. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979192

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis.
Journal
Front Immunol
Year
2026
Publication types
Journal Article, Review
Revised in PubMed
2026-11-05

Source PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leng JJing
2Wang CChenyu
3Bai CChunmei

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Janus Kinase InhibitorsMajor topic
MyocarditisMajor topic
Immune Checkpoint InhibitorsMajor topic
Humans
Animals
Signal Transduction
Janus Kinases

Source PubMed

Download CSV of topics

References82

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139210332Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study.J Transl Med2024https://conductscience.org/library/papers/39210332PubMed
238701735Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization.Cytokine2024https://conductscience.org/library/papers/38701735PubMed
341826213Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide study.Ann Rheum Dis2026https://conductscience.org/library/papers/41826213PubMed
435383117Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.J Immunother Cancer2022https://conductscience.org/library/papers/35383117PubMed
538346306Immune-Related Adverse Events of Immune Checkpoint Inhibitors.Ann Intern Med2024https://conductscience.org/library/papers/38346306PubMed
638486105Prmt7 regulates the JAK/STAT/Socs3 signaling pathway in postmenopausal cardiomyopathy.Exp Mol Med2024https://conductscience.org/library/papers/38486105PubMed
734986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
829567210Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.J Am Coll Cardiol2018https://conductscience.org/library/papers/29567210PubMed
937187275Regulation of the JAK/STAT signaling pathway: The promising targets for cardiovascular disease.Biochem Pharmacol2023https://conductscience.org/library/papers/37187275PubMed
1037020552Case report: Myocarditis in congenital STAT1 gain-of function.Front Immunol2023https://conductscience.org/library/papers/37020552PubMed
1141314979JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study.J Immunother Cancer2025https://conductscience.org/library/papers/41314979PubMed
1241422438Serious Infection Risk With TNF Inhibitors vs. JAK Inhibitors in Rheumatoid Arthritis: A Nationwide Claims-Based Cohort Study.Clin Pharmacol Ther2026https://conductscience.org/library/papers/41422438PubMed
1341419971Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis.Arthritis Res Ther2025https://conductscience.org/library/papers/41419971PubMed
1431960755Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.J Am Heart Assoc2020https://conductscience.org/library/papers/31960755PubMed
1542034889Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence.Semin Arthritis Rheum2026https://conductscience.org/library/papers/42034889PubMed
1639991658Identification of Necroptosis and Immune Infiltration in Heart Failure Through Bioinformatics Analysis.J Inflamm Res2025https://conductscience.org/library/papers/39991658PubMed
1740592184Small molecular inhibitors targeting Janus kinases (JAKs) for the treatment of psoriasis.Eur J Med Chem2025https://conductscience.org/library/papers/40592184PubMed
189287210STATs and gene regulation.Science1997https://conductscience.org/library/papers/9287210PubMed
1933645548Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.J Clin Invest2021https://conductscience.org/library/papers/33645548PubMed
2040794245Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.Dermatol Ther (Heidelb)2025https://conductscience.org/library/papers/40794245PubMed

See all 82 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42979192

GET https://conductscience.org/api/papers/v1/42979192/references?page=2